ResMed (NYSE:RMD) announced today an accelerated launch of cloud-based remote monitoring software for ventilators and Lumis bilevel devices across Europe.
The San Diego–based maker of respiratory support devices has been among a host of ventilator makers rushing to meet demand amid the COVID-19 pandemic. But the company noted that there are also many other people who rely on ResMed ventilators for daily breathing support — people who require regular checkups and support from health and homecare providers. Teleheath and telemonitoring could provide an alternative means on checking up on home ventilator users, according to ResMed.
“As a result of the current crisis, we accelerated the development and release of these new features by several months,” said Odile Bigaignon, ResMed’s European VP of respiratory care marketing.
“Through remote telemonitoring, we want to help clinicians and care providers maintain their quality of care for patients that they cannot physically see during this crisis, as well as to provide an additional layer of safety for both provider and patient by helping them to maintain social distancing,” Bigaignon said in a news release.
The remote monitoring runs through ResMed’s AirView platform. Through AirView, clinicians and care providers can remotely monitor respiratory rate and SpO21, or blood oxygen saturation. The digital health platform is able to work via a connectivity module with any Stellar or Astral ventilator in Europe, and Lumis bilevel devices have a built-in cellular connection to AirView.
ResMed launched the same AirView capabilities for Astral and Stellar in the U.S. last year. The AirCurve 10 Series — the bilevel devices primarily used in the U.S. — have built-in cellular connectivity to support remote monitoring and reporting to AirView.